A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said Wednesday, potentially opening up a new ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

The personalized mRNA shot teaches the body to attack a patient’s specific melanoma cells A new vaccine could soon protect patients from returning skin cancer. In a large clinical trial, patients with ...

Denise Fitzsimmons knew that removing the fast-growing lump above her eyebrow in 2024 didn’t eliminate the possibility that ...

A carefully designed clinical trial that set out to supercharge the immune system’s attack on advanced melanoma has delivered ...

Trials investigating mRNA vaccines for lung cancer, pancreatic cancer and other diseases are already underway.

A personalized melanoma vaccine paired with an immune checkpoint drug cut the risk of the cancer returning by 49 Percent at five years in a key clinical trial, according to researchers involved in the ...

A cancer vaccine may be closer to reality now. Moderna and Merck announced this week that their personalized mRNA melanoma vaccine met key goals in a Phase 3 trial, reducing the risk of the cancer ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna and Merck's mRNA cancer vaccine, combined with the latter's immunotherapy medication Keytruda, showed promise in ...

Interim analysis shows goals were met for recurrence and preventing cancer spread Moderna spikes as much as 160%; Merck jumps 12% Barclays estimates therapy could reach about $3 billion in melanoma ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly ...

A personalized mRNA vaccine for melanoma reduced the risk of the cancer returning in a phase III clinical trial, the companies behind the trial announced this week. The vaccine — which relies on the ...